Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 24
Filter
Add more filters










Publication year range
1.
Nanoscale ; 10(4): 1587-1590, 2018 Jan 25.
Article in English | MEDLINE | ID: mdl-29322141

ABSTRACT

Polydiacetylenic nanofibers (PDA-Nfs) obtained by photopolymerization of surfactant 1 were optimized for intracellular delivery of small interfering RNAs (siRNAs). PDA-Nfs/siRNA complexes efficiently silenced the oncogene Lim-1 in the renal cancer cells 786-O in vitro. Intraperitoneal injection of PDA-Nfs/siLim1 downregulated Lim-1 in subcutaneous tumor xenografts obtained with 786-O cells in nude mice. Thus, PDA-Nfs represent an innovative system for in vivo delivery of siRNAs.


Subject(s)
Kidney Neoplasms/therapy , Nanofibers , Polyacetylene Polymer , RNA, Small Interfering/administration & dosage , Animals , Cell Line, Tumor , Gene Silencing , Injections, Intraperitoneal , LIM-Homeodomain Proteins/metabolism , Mice , Mice, Nude , Transcription Factors/metabolism , Xenograft Model Antitumor Assays
2.
Oncogene ; 30(15): 1753-63, 2011 Apr 14.
Article in English | MEDLINE | ID: mdl-21132009

ABSTRACT

Human clear cell renal cell carcinoma (CCC) remains resistant to therapies. The transcription factor LIM-class homeobox gene Lim1 is required for normal organogenesis, including nephrogenesis, by regulating cell movements, differentiation and growth. Its expression is controlled partly by the sonic hedgehog-Gli signaling pathway, which we have recently shown to be reactivated in human CCC. So far, no study has assessed whether Lim1 may be associated with tumorigenesis. Using a panel of human CCC cell lines expressing or not the von Hippel-Lindau tumor suppressor gene and 44 tumor/normal tissues pairs, we found that Lim1 is constitutively and exclusively reexpressed in tumors. Through Lim1 silencing or overexpressing, we show that Lim1 is a growth and survival factor in human CCC, at least through the activation of oncogenic pathways including the phosphoinositide kinase-3/Akt and nuclear factor-kappaB pathways. More importantly, in nude mice bearing human CCC tumors, Lim1 silencing abolished tumor growth through the same mechanism as in vitro. In Lim1-depleted cells and tumors, cell movements were substantially impaired because of the inhibition of expression of various proteins involved in metastatic spread, such as paxillin or tenascin-C. These findings establish that the developmental marker Lim1 acts as an oncogene in cancer cells and targeting Lim1 may constitute an innovative therapeutic intervention in human CCC.


Subject(s)
Carcinoma, Renal Cell/genetics , Homeodomain Proteins/genetics , Kidney Neoplasms/genetics , Animals , Carcinoma, Renal Cell/pathology , Cell Proliferation , Gene Silencing , Humans , Kidney Neoplasms/pathology , LIM-Homeodomain Proteins , Mice , Mice, Nude , Reverse Transcriptase Polymerase Chain Reaction , Signal Transduction , Transcription Factors
3.
Br J Pharmacol ; 134(6): 1113-36, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11704631

ABSTRACT

The cloning of the so-called 'parathyroid hormone-related protein' (PTHrP) in 1987 was the result of a long quest for the factor which, by mimicking the actions of PTH in bone and kidney, is responsible for the hypercalcemic paraneoplastic syndrome, humoral calcemia of malignancy. PTHrP is distinct from PTH in a number of ways. First, PTHrP is the product of a separate gene. Second, with the exception of a short N-terminal region, the structure of PTHrP is not closely related to that of PTH. Third, in contrast to PTH, PTHrP is a paracrine factor expressed throughout the body. Finally, most of the functions of PTHrP have nothing in common with those of PTH. PTHrP is a poly-hormone which comprises a family of distinct peptide hormones arising from post-translational endoproteolytic cleavage of the initial PTHrP translation products. Mature N-terminal, mid-region and C-terminal secretory forms of PTHrP are thus generated, each of them having their own physiologic functions and probably their own receptors. The type 1 PTHrP receptor, binding both PTH(1-34) and PTHrP(1-36), is the only cloned receptor so far. PTHrP is a PTH-like calciotropic hormone, a myorelaxant, a growth factor and a developmental regulatory molecule. The present review reports recent aspects of PTHrP pharmacology and physiology, including: (a) the identification of new peptides and receptors of the PTH/PTHrP system; (b) the recently discovered nuclear functions of PTHrP and the role of PTHrP as an intracrine regulator of cell growth and cell death; (c) the physiological and developmental actions of PTHrP in the cardiovascular and the renal glomerulo-vascular systems; (d) the role of PTHrP as a regulator of pancreatic beta cell growth and functions, and, (e) the interactions of PTHrP and calcium-sensing receptors for the control of the growth of placental trophoblasts. These new advances have contributed to a better understanding of the pathophysiological role of PTHrP, and will help to identify its therapeutic potential in a number of diseases.


Subject(s)
Islets of Langerhans/metabolism , Parathyroid Hormone/physiology , Proteins/physiology , Receptors, Parathyroid Hormone/physiology , Animals , Apoptosis , Calcium-Binding Proteins/metabolism , Cardiovascular System/metabolism , Cell Nucleus/metabolism , Female , Humans , Kidney/metabolism , Mice , Nuclear Localization Signals , Parathyroid Hormone/genetics , Parathyroid Hormone-Related Protein , Placenta/metabolism , Pregnancy , Proteins/genetics , Rats , Receptors, Parathyroid Hormone/genetics , Trophoblasts/metabolism
4.
Endocrinology ; 142(9): 4096-105, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11517189

ABSTRACT

PTHrP is secreted by most cell types. In addition to a paracrine/autocrine role, PTHrP has "intracrine" actions, entering the nuclear compartment under the direction of a classic bipartite nuclear localization signal. In vascular smooth muscle cells, nuclear entry stimulates mitogenesis. In the current study, we sought to more precisely define the regions of PTHrP required for the activation of mitogenesis in vascular smooth muscle cells. PTHrP deletion mutants missing large regions [i.e. the signal peptide, N terminus (1--36), mid region (38--86), nuclear localization signal, C terminus (108--139), or combinations of the above] were expressed in A-10 vascular smooth muscle cells. The consequences on nuclear localization and proliferation were examined. Deletion of the nuclear localization signal prevented nuclear entry and slowed proliferation. Deletion of the highly conserved N terminus or mid region had no impact on nuclear localization or on proliferation. Deletion of the C terminus had no deleterious effect on nuclear localization but dramatically reduced proliferation. Thus, the nuclear localization signal is both necessary and sufficient for nuclear localization of PTHrP. In contrast, activation of proliferation in vascular smooth muscle cells requires both an intact nuclear localization signal and an intact C terminus. Whereas the nuclear localization signal is required for nuclear entry, the C terminus may serve a trans-activating function to stimulate mitogenesis once inside the nucleus of vascular smooth muscle cells.


Subject(s)
Muscle, Smooth, Vascular/cytology , Muscle, Smooth, Vascular/metabolism , Nuclear Localization Signals/physiology , Proteins/chemistry , Proteins/physiology , Amino Acid Sequence/genetics , Animals , Cell Division/physiology , Cell Line , Cell Nucleus/metabolism , Gene Deletion , Molecular Sequence Data , Mutation/physiology , Parathyroid Hormone-Related Protein , Proteins/genetics , Rats , Structure-Activity Relationship , Tissue Distribution
5.
Semin Perinatol ; 25(2): 76-84, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11339669

ABSTRACT

Parathyroid hormone-related protein (PTHrP) has been discovered as a parathyroid hormone (PTH)-like factor responsible for the humoral hypercalcaemia of malignancies. Further studies revealed that PTHrP is ubiquitously expressed, in mature as well as in developing normal tissues from various species. Although not completely understood, the biological roles of PTHrP concern a variety of domains, including calcium phosphorus metabolism and bone mineralization, smooth muscle relaxation, cell growth and differentiation, and embryonic development. As a poly-hormone, PTHrP is now acknowledged to act via the paracrine, autocrine, and even the intracrine pathways. This review focuses on the main developmental features of the biology of PTHrP. During embryonic development, PTHrP is considered to be involved as a growth factor that promotes cell proliferation and delays cell terminal maturation. PTHrP has been shown to intervene in the development of various tissues and organs such as the skeleton, skin, hair follicles, tooth, pancreas, and the kidney. In addition, through its midregion sequence, which is able to promote an active transplacental calcium transport, PTHrP may intervene indirectly in the mineralization of the foetal skeleton. PTHrP has also been shown to be necessary for the normal development of the mammary gland, while huge amounts of PTHrP are found in the human milk. Finally, observations of physiologic, vasodilating effects of PTHrP in the kidney suggest its involvment in the control of renal hemodynamics, especially in the perinatal period.


Subject(s)
Growth , Proteins/physiology , Animals , Bone Development , Breast/physiology , Cardiovascular System/embryology , Cardiovascular System/growth & development , Embryonic and Fetal Development , Female , Humans , Kidney/embryology , Kidney/growth & development , Parathyroid Hormone-Related Protein , Placenta/physiology , Pregnancy , Proteins/chemistry , Proteins/genetics
6.
FASEB J ; 15(3): 707-18, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11259389

ABSTRACT

In previous studies, added parathyroid hormone-related protein (PTHrP) inhibits whereas transfected PTHrP stimulates the proliferation of A10 aortic smooth muscle cells by nuclear translocation of the peptide. In the present studies, we asked whether these paradoxical trophic actions of PTHrP occur in smooth muscle cells (SMC) cultured from small intrarenal arteries of, and whether they are altered in, 12-wk-old spontaneously hypertensive rats (SHR) as compared to normotensive Wistar-Kyoto (WKY) rats. SHR cells grew faster than WKY cells. PTHrP transcript was increased in SHR-derived cells whereas PTH1 receptor (PTH1R) transcripts were similar in both cell lines. In both strains of cells, stable transfection with human PTHrP(1-139) cDNA did not further induce proliferation, suggesting maximal effect of endogenous PTHrP in wild cells. In contrast, transfection with antisense hPTHrP(1-139) cDNA, which abolished PTHrP mRNA, decreased WKY but increased SHR cell proliferation. Added PTHrP(1-36) (1-100 pM) decreased WKY and increased SHR cell proliferation. Additional studies indicated that the preferential coupling of PTH1-R to G-protein Gi was responsible for the proliferative effect of exogenous PTHrP in SHR cells. Moreover, PTHrP was detected in the nucleolus of a fraction of WKY and SHR renal SMC, in vitro as well as in situ, suggesting that the nucleolar translocation of PTHrP might be involved in the proliferative effects of endogenous PTHrP. In renovascular SMC, added PTHrP is antimitogenic, whereas endogenously produced PTHrP is mitogenic. These paradoxical effects of PTHrP on renovascular SMC proliferation appear to be reversed in the SHR model of genetic hypertension. A new concept emerges from these results, according to which a single molecule may have opposite effects on VSMC proliferation under physiological and pathophysiological conditions.


Subject(s)
Cell Division/drug effects , Hypertension/pathology , Kidney/blood supply , Muscle, Smooth, Vascular/drug effects , Proteins/pharmacology , Receptors, Parathyroid Hormone/metabolism , Animals , Arteries/anatomy & histology , Blotting, Western , Cells, Cultured , Cholera Toxin/pharmacology , Cloning, Molecular , Disease Models, Animal , Humans , Immunohistochemistry , Male , Muscle, Smooth, Vascular/cytology , Muscle, Smooth, Vascular/pathology , Parathyroid Hormone-Related Protein , Proteins/genetics , Proteins/metabolism , Rats , Rats, Inbred SHR , Rats, Inbred WKY , Receptor, Parathyroid Hormone, Type 1 , Receptors, Parathyroid Hormone/genetics , Reverse Transcriptase Polymerase Chain Reaction , Transfection , Virulence Factors, Bordetella/pharmacology
7.
Endocrinology ; 140(9): 4342-50, 1999 Sep.
Article in English | MEDLINE | ID: mdl-10465308

ABSTRACT

Although PTH-related protein-(1-36) [PTHrP-(1-36)] is known to be expressed in smooth muscle and to exert potent myorelaxant effects, its tonic effects on cavernosal smooth muscle has not yet been explored. Using the RT-PCR technique, the present study establishes that PTHrP messenger RNA is present in microdissected corpus cavernosa in the rat. In immunohistochemical studies using affinity-purified antibodies to middle regions of PTHrP, immunostaining was localized throughout the penile structures, including vessels, cavernosal smooth muscle, and trabecular fibroblasts. Strong immunostaining for PTHrP was also detected in the dorsal nerve bundles. In anesthetized rats, intracavernosally injected boluses of increasing doses of PTHrP-(1-36) (0.3-30 pmol in 100 microl saline) had little effect on intracavernosal pressure. However, they markedly potentiated the dilatory response to papaverine (8-800 nmol), increasing the papaverine-induced intracavernous pressure by 2.5-fold, close to the mean arterial pressure. In conclusion, the cavernosal expression of PTHrP messenger RNA, the distribution of immunoreactive PTHrP throughout the structuro-functional components of the erectile apparatus and its strong potentiating action on papaverine-induced cavernosal relaxation, collectively suggest that PTHrP participates in the control of cavernosal tone.


Subject(s)
Penis/metabolism , Proteins/metabolism , Animals , Immunohistochemistry , In Vitro Techniques , Male , Parathyroid Hormone-Related Protein , Penis/physiology , Peptide Fragments/pharmacology , Pressure , Proteins/genetics , Proteins/pharmacology , RNA, Messenger/metabolism , Rats , Rats, Wistar , Reverse Transcriptase Polymerase Chain Reaction , Tissue Distribution/physiology
9.
Recent Prog Horm Res ; 53: 305-38; discussion 338-40, 1998.
Article in English | MEDLINE | ID: mdl-9769713

ABSTRACT

Parathyroid hormone-related protein was discovered as the causative agent responsible for the common paraneoplastic syndrome, humoral hypercalcemia of malignancy. It is now clear that the PTHrP gene is expressed in virtually every cell and tissue in the body at some point in development or adult life and that the peptide is critical for normal life. Two of the tissues that produce PTHrP are the insulin-producing beta cells of the pancreatic islet and the vascular smooth muscle cells of the arterial wall. In this review, the physiologic roles of PTHrP in the islet and in the arterial wall are explored. PTHrP is a classical neuroendocrine prohormone that undergoes extensive post-translational processing to yield a family of daughter peptides that are the mature secretory forms of the peptide. In addition to its ability to act as a traditional endocrine, paracrine, or autocrine factor, PTHrP appears to be able to act as an "intracrine" factor as well, directly entering the nucleus after translation and stimulating proliferation, apoptosis, and perhaps other cellular responses as well. The cell biology underlying this phenomenon is also explored herein.


Subject(s)
Cardiovascular Physiological Phenomena , Islets of Langerhans/physiology , Proteins/physiology , Animals , Base Sequence , Endothelium, Vascular/physiology , Humans , Mice , Molecular Sequence Data , Parathyroid Hormone-Related Protein
10.
Kidney Int Suppl ; 67: S207-10, 1998 Sep.
Article in English | MEDLINE | ID: mdl-9736292

ABSTRACT

Parathyroid hormone-related protein (PTHrP) is expressed throughout the renovascular system, and it dilates renal vessels, increases renal blood flow and glomerular filtration rate, and stimulates renin release. Mechanical forces and experimental hypertension have been shown to stimulate PTHrP expression in smooth muscles, suggesting a negative feedback control of vascular tone by PTHrP in hypertension. In this study, we compared the impact of a PTHrP receptor antagonist, PTHrP (7-34), and a PTHrP receptor agonist, PTHrP (1-36), on the vascular resistance of perfused kidneys isolated from spontaneously hypertensive rats (SHR) and Wistar Kyoto rats (WKY). Endogenous PTHrP appears not to act as a renal vasodilator in either WKY or SHR. However, the vasodilation following infused PTHrP (1-36) is blunted markedly in SHR, possibly due to desensitization or down-regulation of PTH/PTHrP receptors. Negative feedback control of vascular tone by PTHrP in SHR thus appears unlikely. The results raise the question of whether endogenous renovascular PTHrP behaves rather as a growth factor than as a vasodilator.


Subject(s)
Hypertension, Renal/physiopathology , Kidney/blood supply , Proteins/pharmacology , Renal Circulation/drug effects , Vasodilation/drug effects , Animals , Feedback/physiology , Growth Substances/physiology , Kidney/chemistry , Kidney/physiopathology , Male , Organ Culture Techniques , Parathyroid Hormone-Related Protein , Phenylephrine/pharmacology , Rats , Rats, Inbred SHR , Rats, Inbred WKY , Receptors, Parathyroid Hormone/physiology , Vascular Resistance , Vasoconstrictor Agents/pharmacology
11.
Curr Opin Nephrol Hypertens ; 7(1): 27-32, 1998 Jan.
Article in English | MEDLINE | ID: mdl-9442359

ABSTRACT

Parathyroid hormone-related protein (PTHrP) appears to play crucial roles in the cardiovascular system. Over the past few years it has become apparent that there is more than one receptor recognizing parathyroid hormone or PTHrP, or both, and that PTHrP is not only a potent vasodilator of vascular smooth muscle cell tone, but is also a regulator of vascular smooth muscle cell proliferation and a secretagogue of renin and vasopressin. Investigators in several laboratories have started to query whether PTHrP intervenes in vascular diseases such as hypertension, (re)stenosis-atherosclerosis and endotoxaemia.


Subject(s)
Growth Substances/physiology , Muscle, Smooth/physiology , Parathyroid Hormone/physiology , Proteins/physiology , Animals , Humans , Muscle Tonus/physiology , Parathyroid Hormone-Related Protein , Signal Transduction/physiology
12.
Pediatr Res ; 42(4): 550-5, 1997 Oct.
Article in English | MEDLINE | ID: mdl-9380452

ABSTRACT

Studies were performed on isolated perfused kidneys (IPK) from postnatal developing rabbits to ask 1) whether the high renal vascular resistance (RVR) at birth involves intrinsic renal mechanisms, 2) whether nitric oxide (NO) release is involved in the modulation of renal vascular tone, and 3) whether NO modulates exogenous angiotensin II (AII)-induced vasoconstrictions. Kidneys isolated from 1-wk-old (during nephrogenesis), 3-wk-old (after nephrogenesis), and 6-wk-old rabbits were perfused in the presence of 10(-5) M indomethacin. RVR decreased with age from 12.7 +/- 0.6 at 1 wk to 10.1 +/- 0.5 mm Hg min g mL-1 at 6 wk. N omega-Nitro-L-arginine methyl ester (L-NAME, 10(-4) M) comparably increased RVR by about 30% at 1, 3, and 6 wk. The vasoconstrictions induced by 10(-8) M AII increased basal pressure from 28% at 1 wk to 78% at 6 wk and were potentiated by L-NAME by about 100%. In contrast, the vasoconstrictions induced by 10(-10) M AII decreased from 8% at 1 wk to 0% at 6 wk and were potentiated by L-NAME by about 250% at 1 and 3 wk. We conclude that during postnatal development: 1) RVR in IPK decreases in absence of AII and extrarenal influences, suggesting that high RVR at birth involves intrinsic mechanisms, 2) L-Arg/NO modulates basal tonus in developing IPK, and, 3) renal vasoconstrictor responses to exogenous AII are buffered by NO at early postnatal stages and follow an AII concentration-dependent developmental pattern. A specific neonatal high affinity AII/NO interaction disappearing after nephrogenesis completion precedes a low affinity AII/NO interaction, which progressively increases toward adult ages. These findings are in favor of a specific involvement of AII-NO interactions in the control of developing renal hemodynamics.


Subject(s)
Kidney/blood supply , Kidney/drug effects , Vascular Resistance/drug effects , Vascular Resistance/physiology , Age Factors , Angiotensin II/pharmacology , Animals , Animals, Newborn , Enzyme Inhibitors/pharmacology , In Vitro Techniques , NG-Nitroarginine Methyl Ester/pharmacology , Nitric Oxide/pharmacology , Perfusion , Rabbits , Vasoconstriction/drug effects , Vasoconstrictor Agents/pharmacology
13.
Proc Natl Acad Sci U S A ; 94(25): 13630-5, 1997 Dec 09.
Article in English | MEDLINE | ID: mdl-9391077

ABSTRACT

Parathyroid hormone-related protein (PTHrP) is a prohormone that is posttranslationally processed to a family of mature secretory forms, each of which has its own cognate receptor(s) on the cell surface that mediate the actions of PTHrP. In addition to being secreted via the classical secretory pathway and interacting with cell surface receptors in a paracrine/autocrine fashion, PTHrP appears to be able to enter the nucleus directly following translation and influence cellular events in an "intracrine" fashion. In this report, we demonstrate that PTHrP can be targeted to the nucleus in vascular smooth muscle cells, that this nuclear targeting is associated with a striking increase in mitogenesis, that this nuclear effect on proliferation is the diametric opposite of the effects of PTHrP resulting from interaction with cell surface receptors on vascular smooth muscle cells, and that the regions of the PTHrP sequence responsible for this nuclear targeting represent a classical bipartite nuclear localization signal. This report describes the activation of the cell cycle in association with nuclear localization of PTHrP in any cell type. These findings have important implications for the normal physiology of PTHrP in the many tissues which produce it, and suggest that gene delivery of PTHrP or modified variants may be useful in the management of atherosclerotic vascular disease.


Subject(s)
Cell Nucleus/drug effects , Eye Proteins , Intercellular Signaling Peptides and Proteins , Membrane Proteins/metabolism , Membrane Proteins/physiology , Mitogens/antagonists & inhibitors , Mitogens/pharmacology , Muscle, Smooth, Vascular/cytology , Muscle, Smooth, Vascular/drug effects , Parathyroid Hormone/pharmacology , Proteins/pharmacology , Adaptor Proteins, Signal Transducing , Amino Acid Sequence , Animals , Cattle , Cell Nucleus/metabolism , Cells, Cultured , Humans , Immunohistochemistry , Membrane Proteins/genetics , Mice , Mice, Knockout , Muscle, Smooth, Vascular/metabolism , Parathyroid Hormone/genetics , Parathyroid Hormone/metabolism , Parathyroid Hormone-Related Protein , Proteins/genetics , Proteins/metabolism , Rats , Sequence Deletion , Transfection
14.
Kidney Int ; 50(5): 1591-603, 1996 Nov.
Article in English | MEDLINE | ID: mdl-8914026

ABSTRACT

The presence of parathyroid hormone-related protein (PTHrP) in human kidney vasculature and the signal transduction pathways stimulated during PTHrP-induced vasodilation of the rabbit kidney were investigated. Immunostaining of human kidney revealed the abundant presence of PTHrP in media and intima of all microvessels as well as in macula densa. In isolated perfused rabbit kidney preconstricted with noradrenaline, 10(-5) M Rp-cAMPS, a direct inhibitor of protein kinase A, produced comparable inhibition of 2.5 x 10(-7) M forskolin- and 10(-7) M PTHrP-induced vasorelaxations. Renal vasorelaxation and renal microvessel adenylyl cyclase stimulation underwent comparable desensitization following exposure to PTHrP. Nitric oxide (NO)-synthase inhibition by L-NAME (10(-4) M), NO scavenging by an imidazolineoxyl N-oxide (10(-4) M) and guanylyl cyclase inhibition by methylene blue (10(-4) M) decreased PTHrP-induced vasorelaxation by 27 to 53%, abolished bradykinin-induced vasorelaxation and did not affect forskolin-induced vasorelaxation. The effects of Rp-cAMPS and L-NAME were not additive on PTHrP-induced vasorelaxation. Damaging endothelium by treating the kidney with either anti-factor VIII-related antibody and complement, gossypol or detergent, did not affect PTHrP- or forskolin-induced vasorelaxations but reduced bradykinin-induced vasorelaxation by 53 to 92%. Conversely, endothelial damage did not alter the inhibitory action of L-NAME on PTHrP-induced vasorelaxation. In conclusion, PTHrP is present throughout the human renovascular tree and juxtaglomerular apparatus. Activation of both adenylyl cyclase/protein kinase A and NO-synthase/guanylyl cyclase pathways are directly linked to the renodilatory action of PTHrP in a way that does not require an intact endothelium in the isolated rabbit kidney.


Subject(s)
Cyclic AMP/metabolism , Nitric Oxide/metabolism , Proteins/analysis , Proteins/metabolism , Renal Circulation/physiology , Adenylyl Cyclases/metabolism , Animals , Cyclic AMP-Dependent Protein Kinases/metabolism , Endothelium, Vascular/drug effects , Endothelium, Vascular/physiology , Enzyme Inhibitors/pharmacology , Female , Humans , Immunohistochemistry , In Vitro Techniques , Male , Nitric Oxide Synthase/antagonists & inhibitors , Nitric Oxide Synthase/metabolism , Parathyroid Hormone-Related Protein , Rabbits , Signal Transduction/physiology , Vasodilation/physiology
15.
J Biol Chem ; 271(40): 24371-81, 1996 Oct 04.
Article in English | MEDLINE | ID: mdl-8798692

ABSTRACT

Parathyroid hormone-related protein (PTHrP) is initially translated as a preprohormone which is posttranslationally processed to yield a family of mature secretory forms. Most attention has focused on the amino-terminal portion of the molecule which is homologous to parathyroid hormone. It is clear, however, that a mid-region species of PTHrP is posttranslationally cleaved from the highly conserved mid-region of PTHrP, and that the amino terminus of this peptide is Ala38. The purposes of the current study were three: 1) to confirm that Arg37 immediately preceding Ala38 serves as a posttranslational processing site in the PTHrP precursor, 2) to determine the carboxyl terminus of the mid-region secretory species of PTHrP, and 3) to synthesize this authentic mid-region secretory form of PTHrP and determine whether it is biologically active. The results indicate that: 1) Arg37 is indeed a processing site in the PTHrP precursor; 2) three distinct mid-region PTHrP species are generated by posttranslational processing, PTHrP(38-94)amide, PTHrP(38-95), and most likely, PTHrP(38-101); and 3) synthetic mid-region PTHrP(38-94)amide is active in four different biological systems. These studies confirm the finding that PTHrP is a prohormone. More importantly, they define a novel, biologically active highly conserved mid-region secretory form of PTHrP.


Subject(s)
Proteins/chemistry , Proteins/physiology , Amino Acid Sequence , Animals , Arginine/chemistry , Molecular Sequence Data , Mutagenesis, Site-Directed , Parathyroid Hormone-Related Protein , Peptide Fragments/chemistry , Peptide Fragments/physiology , Peptide Mapping , Proteins/genetics , Rats , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization , Trypsin/chemistry , Tumor Cells, Cultured
16.
Br J Pharmacol ; 118(8): 1995-2000, 1996 Aug.
Article in English | MEDLINE | ID: mdl-8864534

ABSTRACT

1. Parathyroid hormone-related protein (PTHrP) is expressed in the kidney and acts on vascular PTH/ PTHrP receptors to vasodilate the isolated kidney and to stimulate renin release. However, effects of PTHrP on renal blood flow (RBF) and glomerular filtration rate (GFR) in vivo have not been assessed in the absence of its cardiac, peripheral and central effects. We investigated the renal effects of PTH and PTHrP infused into the left renal artery of anaesthetized rats. 2. Intrarenal infusions, adjusted to generate increasing concentrations of human PTHrP(1-34) and rat PTH(1-34) in renal plasma (2 x 10(-11) to 6 x 10(-9) M) produced a comparable dose-dependent increase in RBF. The rise was 4% at the lowest and 34% at the highest concentrations of peptides. Up to a concentration of 2 x 10(-9) M, mean arterial pressure (MAP) and heart rate were not affected, but at 6 x 10(-9) M, intrarenally infused peptides reached the peripheral circulation, and caused a fall in MAP within a few minutes. While MAP returned to basal value after the last peptide infusion, RBF remained more than 10% above control for at least 30 min. 3. Two competitive PTH/PTHrP receptor antagonists, [Nle8,18, Tyr34]-bPTH(3-34)amide and [Leu11, D-Trp12]-hPTHrP(7-34)amide (2 x 10(-8) M) were devoid of agonist activity, but markedly antagonized the dose-dependent increase in RBF elicited by PTHrP. 4. GFR and urine flow were measured in left PTHrP-infused experimental kidney and right control kidney. Renal PTHrP concentration of 10(-10) M elevated left RBF by 10%, and GFR by 20% without significantly increasing filtration fraction, and increased urine flow by 57%. In the right control kidney GFR and diuresis did not change. 5. The results indicate that PTHrP has similar renal haemodynamic effects as PTH and increases RBF, GFR and diuresis in anaesthetized rats.


Subject(s)
Kidney/drug effects , Parathyroid Hormone/pharmacology , Proteins/pharmacology , Renal Circulation/drug effects , Animals , Blood Pressure/drug effects , Dose-Response Relationship, Drug , Female , Heart Rate/drug effects , Parathyroid Hormone-Related Protein , Rats , Rats, Wistar
19.
J Physiol ; 483 ( Pt 2): 481-90, 1995 Mar 01.
Article in English | MEDLINE | ID: mdl-7650615

ABSTRACT

1. The effects of locally applied parathyroid hormone-related protein (PTHRP), a putative autocrine/paracrine hormone, on vascular diameters and glomerular blood flow (GBF) in the split hydronephrotic rat kidney were studied. As PTHRP interacts with parathyroid hormone (PTH) receptors in all tissues tested so far, the effects of PTHRP were compared with those of PTH. 2. Preglomerular vessels dilated in a concentration- and time-dependent manner that was almost identical for PTH and PTHRP. A significant preglomerular vasodilation (5-17%) occurred at a threshold concentration of 10(-10) mol l-1 PTH or PTHRP, which raised GBF by 20 +/- 2 and 31 +/- 4%, respectively (means +/- S.E.M., n = 6). PTH or PTHRP (10(-7) mol l-1) increased preglomerular diameters (11-36%) and GBF (60 +/- 10 and 70 +/- 8%, respectively) to near maximum. The most prominent dilatation was located at the interlobular artery and at the proximal afferent arteriole. 3. Efferent arterioles were not affected by either PTH or PTHRP. 4. Estimated concentrations of half-maximal response (EC50) for preglomerular vasodilatation and GBF increase were in the nanomolar to subnanomolar range. 5. After inhibition of angiotensin I-converting enzyme by 2 x 10(-6) mol kg-1 quinapril I.V. (n = 6), 10(-8) mol l-1 PTHRP dilated preglomerular vessels and efferent arterioles (9 +/- 1% proximal and 6 +/- 1% distal). 6. We conclude that the renal vasculature of the hydronephrotic kidney is highly sensitive to vasodilatation by PTH and PTHRP, which, in addition, may constrict efferent arterioles by stimulating renin release.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Hydronephrosis/physiopathology , Kidney/blood supply , Parathyroid Hormone/pharmacology , Proteins/pharmacology , Angiotensin-Converting Enzyme Inhibitors/pharmacology , Animals , Blood Pressure , Dose-Response Relationship, Drug , Female , Kidney Glomerulus/blood supply , Parathyroid Hormone-Related Protein , Rats , Rats, Wistar , Renal Circulation/drug effects , Vasodilation/physiology
20.
Clin Sci (Lond) ; 86(3): 245-9, 1994 Mar.
Article in English | MEDLINE | ID: mdl-8156733

ABSTRACT

1. The present study was designed to explore the role of NO derived from L-arginine in the vasodilatory response to synthetic human parathyroid hormone-related peptide-(1-34) in the isolated rabbit kidney perfused in the presence of indomethacin (10 mumol/l) and preconstricted with noradrenaline (7.2 nmol/min). 2. Under control conditions, bolus administrations of acetylcholine (10 mumol/l), an NO-dependent renal vasodilator, verapamil (0.1 mmol/l), an NO-independent renal vasodilator, and parathyroid hormone-related peptide (87 nmol/l) decreased the preconstriction pressure, by 31%, 71% and 43%, respectively. 3. Bolus administration of 100 mumol/l NG-nitro-L-arginine-methyl ester caused a 20% increment in the perfusion pressure of the noradrenaline-preconstricted kidney. NG-nitro-L-arginine methyl ester inhibited the vasodilatory effect of acetylcholine and parathyroid hormone-related peptide, by 68% and 44%, respectively, but did not alter the verapamil-induced vasodilatation. 4. Unlike L-arginine, the bolus administration of 1 mumol/l of a mono-substituted L-arginine derivative, N-alpha-benzoyl-L-arginine ethyl ester, durable decreased the noradrenaline/NG-nitro-L-arginine methyl ester-induced preconstriction by 57%. 5. Both L-arginine and N-alpha-benzoyl-L-arginine ethyl ester effectively reversed the inhibition induced by NG-nitro-L-arginine methyl ester on the vasodilatation elicited by acetylcholine and parathyroid hormone-related peptide. 6. In conclusion, the formation of NO from L-arginine contributes a substantial part to the vasodilatory action of parathyroid hormone-related peptide. Therefore, parathyroid hormone-related peptide appears to have a place among the renal haemodynamically active substances, whose vasodilatory actions are tuned by NO.


Subject(s)
Arginine/analogs & derivatives , Nitric Oxide/metabolism , Parathyroid Hormone/pharmacology , Proteins/pharmacology , Vasodilation/physiology , Acetylcholine/pharmacology , Animals , Arginine/pharmacology , Female , Kidney/drug effects , Male , NG-Nitroarginine Methyl Ester , Organ Culture Techniques , Parathyroid Hormone-Related Protein , Perfusion , Rabbits , Vasodilation/drug effects , Verapamil/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...